Nike (NKE) is down more than -2% after TD Cowen cut its price target on the stock to $73 from $78. Neurogene (NGNE) is down more than -39% after it paused the use of the higher 3E15 vg dose of its NGN ...
Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) ...
TD Cowen lowered the firm’s price target on Nike (NKE) to $73 from $78 and keeps a Hold rating on the shares. The firm says meetings with ...
Nike's once red-hot Jordan Brand could be losing its cool. In the last five years, Jordan Brand has more than doubled its top ...
Michael Saylor’s bold move to convert MicroStrategy’s treasury into Bitcoin has catapulted the company into the top tier of ...
Komp covers the Consumer Cyclical sector, focusing on stocks such as Nike, Deckers Outdoor ... In a report released today, TD Cowen also maintained a Buy rating on the stock with a $60.00 price target ...
On Holding stock price is hovering near its highest level on record as the company’s growth trajectory gains momentum. ONON ...
XML Financial LLC bought a new position in shares of NIKE, Inc. (NYSE:NKE – Free Report) in the third quarter, according to ...
In contrast, Ross Stores, whose business is healthier than Estée Lauder's though softer than that of its direct rivals, chose ...
As previously reported, TD Cowen analyst Mario Mendonca upgraded Scotiabank (BNS) to Buy from Hold with an C$80 price target The firm, which believes ROE is “among the most important financial ...
TD Cowen downgrades shares to Hold from Buy with a $180 price target, slashed from $290, expecting the company's shipbuilding execution challenges will linger, reducing absolute margin levels for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback